Oral compositions of MK2 pathway inhibitor for treatment of immune conditions
US12370195B2 · kind B2 · utility
0Cited by
9References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 8, 2023 |
| Grant date | Jul 29, 2025 |
| Priority date | — |
| Expiry date | Nov 8, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to oral compositions of Compound I or a derivative thereof. Methods of use for treating an inflammatory condition are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.